76,260 Shares in Elanco Animal Health Incorporated $ELAN Acquired by N.F.U. MUTUAL UNIT MANAGERS Ltd

N.F.U. MUTUAL UNIT MANAGERS Ltd purchased a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 76,260 shares of the company’s stock, valued at approximately $1,707,000.

Several other hedge funds and other institutional investors have also bought and sold shares of ELAN. AlphaGrep UK Ltd bought a new stake in shares of Elanco Animal Health during the 3rd quarter worth $356,000. Benjamin Edwards Inc. increased its holdings in Elanco Animal Health by 20.0% during the third quarter. Benjamin Edwards Inc. now owns 32,239 shares of the company’s stock worth $722,000 after buying an additional 5,380 shares during the last quarter. First Trust Advisors LP raised its position in Elanco Animal Health by 144.3% in the third quarter. First Trust Advisors LP now owns 835,300 shares of the company’s stock worth $18,702,000 after acquiring an additional 493,382 shares during the period. State Street Corp raised its position in Elanco Animal Health by 1.4% in the third quarter. State Street Corp now owns 16,285,257 shares of the company’s stock worth $364,627,000 after acquiring an additional 222,211 shares during the period. Finally, Resona Asset Management Co. Ltd. bought a new stake in Elanco Animal Health in the third quarter worth about $35,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Price Performance

ELAN opened at $25.78 on Friday. The company has a market capitalization of $12.89 billion, a price-to-earnings ratio of -85.93, a PEG ratio of 2.18 and a beta of 1.73. The company has a quick ratio of 1.07, a current ratio of 2.09 and a debt-to-equity ratio of 0.55. The firm has a 50-day moving average price of $23.64 and a 200-day moving average price of $23.92. Elanco Animal Health Incorporated has a twelve month low of $19.40 and a twelve month high of $27.98.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.07. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.21 billion. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.80%. The company’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.19 earnings per share. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. Equities analysts expect that Elanco Animal Health Incorporated will post 1.18 EPS for the current year.

Elanco Animal Health declared that its Board of Directors has authorized a stock buyback plan on Thursday, November 19th that authorizes the company to repurchase $600 million in shares. This repurchase authorization authorizes the company to reacquire up to 4.5% of its shares through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, insider Timothy Bettington sold 4,350 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.00, for a total transaction of $100,050.00. Following the sale, the insider owned 138,911 shares in the company, valued at $3,194,953. This represents a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.14% of the stock is owned by insiders.

Analysts Set New Price Targets

ELAN has been the subject of a number of research reports. KeyCorp reissued an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, November 9th. Jefferies Financial Group cut shares of Elanco Animal Health from a “buy” rating to a “hold” rating and lowered their price target for the stock from $31.00 to $24.00 in a report on Tuesday, October 20th. Barclays upped their price objective on Elanco Animal Health from $30.00 to $32.00 and gave the company an “overweight” rating in a research note on Thursday. The Goldman Sachs Group assumed coverage on Elanco Animal Health in a report on Friday, October 16th. They set a “buy” rating and a $32.00 price objective for the company. Finally, UBS Group increased their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $30.36.

Check Out Our Latest Analysis on ELAN

Top Elanco Animal Health Stories

These are some of the ELAN stories that stood out recently:

  • Positive Sentiment: Elanco authorized its first share repurchase program, allowing it to buy back up to $600 million of stock—up to 4.5% of shares outstanding. The company cited stronger cash generation, balance-sheet improvement and confidence in continued business momentum. Buybacks can support earnings per share and signal management confidence. Elanco Announces Inaugural $600 Million Share Repurchase Authorization
  • Positive Sentiment: Barclays raised its price target to $32 from $30 and maintained an “overweight” rating, signaling a more optimistic view of the shares. Barclays stock recommendations

About Elanco Animal Health

(Free Report)

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

Featured Stories

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.